Grilled Cheese

ExploreLog inSign up
Terms of UsePrivacy PolicyCommunity StandardsHelpGet the app

Grilled Cheese is a product of Village Compute

Version devBuilt at: 2026-10-16 08:00:47 EDT

PhotosVideosAllPeople
LatestRanked
@medthority.bsky.socialOct 1, 2026, 9:30 AM

What were the biggest #SCLC highlights from #WCLC2026? Watch Giannis Mountzios share his perspective on the MAVERICK trial, novel antibody-drug conjugates, and evolving treatment strategies that are reshaping the care landscape

https://ow.ly/likl50ZTplF

Photo, no description
@cancertherapyadv.bsky.socialSep 18, 2026, 4:31 PM

First-line trastuzumab deruxtecan (T-DXd) prolongs PFS, but not overall survival, in metastatic, HER2-mutant #NSCLC

Julia Rotow, MD, from @danafarber.bsky.social presented research from the DESTINY-Lung 04 trial this week at #WCLC2026 @iaslc.bsky.social

Full article: https://bit.ly/4gY7oK6

@onc-rg.bsky.socialSep 18, 2026, 1:34 PM

Join our team as we break down the major readouts from WCLC 2026 and discuss what key signals to watch for as we head into ESMO 2026!
Register: events.teams.microsoft.com/event/681070...

#WCLC2026 #ESMO2026 #LungCancer #Oncology

ONCrg Live Event: WCLC Insights into ESMO Signals 📅 Date: Wednesday, Oct 7th at 1pm ET Join our team as we break down the major readouts from WCLC 2026 and discuss what key signals to watch for as we head into ESMO 2026! 👇 What specific topics or questions are you hoping we cover during the live event? Let us know in the comments or when you register for the event! #WCLC2026 #ESMO2026 #LungCancer #Oncology #clinicalinsights #competitiveintelligence #nsclc #sclc #oncrg #bprg
@ipharmaservices.bsky.socialSep 17, 2026, 3:46 PM

DESTINY-Lung04：#Enhertu 在1L HER2突变 #非小细胞肺癌 击败化疗+帕博利珠单抗。
• PFS: 14.3 vs 8.3月
• ORR: 70% vs 44.5%
• OS: 29.3 vs 33.1月

www.ipharmacenter.com/post/iaslc-2...

#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #新闻 #媒体 #肺癌

@ipharmaservices.bsky.socialSep 17, 2026, 3:44 PM

DESTINY-Lung04: #Enhertu supera quimio+pembro em 1L #CPNPC HER2+
• SLP: 14,3 vs 8,3m
• TRO: 70% vs 44,5%
• SG: 29,3 vs 33,1m

www.ipharmacenter.com/post/iaslc-2...

#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #notícias #mídia #CâncerDePulmão

@ipharmaservices.bsky.socialSep 17, 2026, 3:44 PM

DESTINY-Lung04: #Enhertu batte chemio+pembro in 1L #NSCLC HER2+ • PFS: 14,3 vs 8,3m • ORR: 70% vs 44,5% • OS: 29,3 vs 33,1m

www.ipharmacenter.com/post/iaslc-2...

#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #notizie #media #TumoreAlPolmone

@ipharmaservices.bsky.socialSep 17, 2026, 2:29 PM

DESTINY-Lung04: #Enhertu schlägt Chemo+Pembro in 1L HER2+ #NSCLC
• PFS: 14,3 vs 8,3M
• ORR: 70% vs 44,5%
• OS: 29,3 vs 33,1M

www.ipharmacenter.com/post/iaslc-2...

#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #Nachrichten #Medien #Lungenkrebs

@ipharmaservices.bsky.socialSep 17, 2026, 2:29 PM

DESTINY-Lung04 : #Enhertu bat chimio+pembro en 1L #CBNPC HER2+
• SSP : 14,3 vs 8,3m
• TRG : 70% vs 44,5%
• SG : 29,3 vs 33,1m

www.ipharmacenter.com/post/iaslc-2...

#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #news #media #CancerDuPoumon #HER2

@ipharmaservices.bsky.socialSep 17, 2026, 2:28 PM

DESTINY-Lung04: #Enhertu supera quimio+pembro en 1L #CPNM HER2+
• SLP: 14,3 vs 8,3m
• TRO: 70% vs 44,5%
• SG: 29,3 vs 33,1m

www.ipharmacenter.com/post/iaslc-2...

#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #news #media #CĂĄncerDePulmĂłn #HER2

@trackerbiobank.bsky.socialSep 15, 2026, 10:59 PM

🌏 That’s a wrap on #WCLC2026!

Congratulations to Dr Stephen Wong on a fantastic poster, highlighting methylation differences between immunotherapy responders and non-responders and potential biomarkers of treatment response and resistance in lung cancer. 👏

#LungCancer #Biobank

Photo, no description
@cancertherapyadv.bsky.socialSep 15, 2026, 6:52 PM

Phase 3 REZILIENT3 trial results presented at #WCLC2026:

Adding the TKI zipalertinib to 1L chemotherapy improves outcomes in EGFR ex20ins #NSCLC:
• Median PFS: 14.5 vs 8.5 mos
• ORR: 65.0% vs 40.3%
• Median DOR: 14.2 vs 9.9 mos

Full Article: https://bit.ly/46pC3Kk

Photo, no description
@ipharmaservices.bsky.socialSep 15, 2026, 6:11 PM

Ph3 DESTINY-Lung04: #Enhertu erzielt 14,3 Mo. mPFS vs. 8,3 Mo. mit #Pembrolizumab + Chemo bei 1L HER2-mutiertem #NSCLC (37% geringeres Risiko Progress/Tod).
www.ipharmacenter.com/post/iaslc-2...
#WCLC2026 #WCLC26

@ipharmaservices.bsky.socialSep 15, 2026, 6:11 PM

DESTINY-Lung04 (Ph3) : #Enhertu atteint 14,3 m de SSP vs 8,3 m sous #pembrolizumab + chimio en 1L dans le #CPNPC mutÊ HER2 (-37% risque dÊcès/progression)
www.ipharmacenter.com/post/iaslc-2...
#WCLC2026 #WCLC26 #Oncologie

@ipharmaservices.bsky.socialSep 15, 2026, 6:10 PM

#Enhertu alcanzĂł 14,3 meses de mediana de SLP vs 8,3 meses con #pembrolizumab + quimio en 1L para #CPCNP con mutaciĂłn HER2
www.ipharmacenter.com/post/iaslc-2...
#WCLC2026 #WCLC26 #OncologĂ­a

@cancers-mdpi.bsky.socialSep 15, 2026, 7:42 AM

🤗We were delighted to meet with our editors in person at #WCLC2026!

Thank you for the insightful conversations and continued support in advancing high-quality research in lung cancer✨
#LungCancer #ThoracicOncology #CancersMDPI

Photo, no descriptionPhoto, no description
@firstwordgroup.comSep 15, 2026, 4:36 AM

Roche, MediLink's ADC boost survival in relapsed SCLC $RHHBY #WCLC2026 firstwordpharma.com/story/7990444

@firstwordgroup.comSep 15, 2026, 4:34 AM

J&J's Rybrevant shows numerical OS gain in difficult-to-treat lung cancer $JNJ #WCLC2026 firstwordpharma.com/story/7989702

@firstwordgroup.comSep 15, 2026, 4:33 AM

BioNTech, OncoC4 tout survival benefit for anti-CTLA-4 in NSCLC $BNTX #WCLC2026 firstwordpharma.com/story/7987350

@firstwordgroup.comSep 15, 2026, 4:32 AM

Enhertu's PFS lung cancer win comes with an OS question mark $AZN $DSNKY #WCLC2026 firstwordpharma.com/story/7990485

@cancertherapyadv.bsky.socialSep 14, 2026, 10:10 PM

New phase 3 ARTEMIS-008 trial results presented at #WCLC2026:

Risvutatug rezetecan (ris-rez) significantly improved median overall survival vs. topotecan in relapsed small cell lung cancer (18.5 vs. 10.3 months). 🫁

Read the full article: https://bit.ly/3URwcuE

Load more